Anti-synthetase Syndrome with Dermatomyositis Responding to Combination of Mycophenolate mofetil and Cyclosporin: A Case Report.
DOI:
https://doi.org/10.70672/q65hxt20Keywords:
Anti-synthetase syndrome, dermatomyositis, polymyositis, anti-aminoacyl-tRNA synthetase, anti-Jo1 antibody, mechanic’s hands, interstitial lung disease, corticosteroid, mycophenolate mofetil, cyclosporin.Abstract
Anti-synthetase syndrome (ASS) is a rare inflammatory muscle disorder associated with dermatomyositis and polymyositis, characterized by autoantibodies targeting aminoacyl-tRNA synthetases. Clinical manifestations vary but typically include mechanic’s hands, interstitial lung disease (ILD), and Raynaud’s phenomenon. We report the case of a 42-year-old woman with a positive anti-Jo1 autoantibody, who initially presented with respiratory symptoms that progressed to myositis, along with severe, painful mechanic’s hands and feet. Her condition improved with a combination of mycophenolate mofetil (MMF), corticosteroids, and cyclosporine.
References
[1].Legout L, Fauchais AL, Hachulla E, Queyrel V, Michon-Pasturel U, Lambert M, et al. The antisynthetase syndrome: a subgroup of inflammatory myopathies not to be unrecognized. Rev Med Interne. 2002;23:273–82.
[2].Cavagna L, Nuño L, Scirè CA, Govoni M, Longo FJL, Franceschini F, et al. Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study. Medicine (Baltimore). 2015, 94:e1144.
[3].Gusdorf L, Morruzzi C, Goetz J, Lipsker D, Sibilia J, Cribier B. Mechanics hands in patients with antisynthetase syndrome: 25 cases. Ann Dermatol Venereol. 2019;146(1):19–25.
[4].Shi J, Li S, Yang H, Zhang Y, Peng Q, Lu X, et al. Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies. J Rheumatol. 2017;47(7):1051–7.
[5].Ji SY, Zeng FQ, Guo Q, Tan GZ, Tang HF, Luo YJ, et al. Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study. Chin Med J (Engl). 2010;123(5):517–22.
[6].Solomon J, Swigris JJ, Brown KK. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol. 2011;37:100–9.
[7].Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-347.
[8].Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-407.
[9].Katzap E, Barilla-LaBarca ML, Marder G. Antisynthetase syndrome. Curr Rheumatol Rep 2011;13:175-81.
[10].Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 2014; 73:227–232.
[11].Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, Albayda J, Paik JJ, Johnson C, et al. A longitudinal cohort study of the anti-synthetase syndrome: Increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology 2017; 56:999–1007.
[12].Waseda Y, Johkoh T, Egashira R, Sumikawa H, Saeki K, Watanabe S, et al. Antisynthetase syndrome: Pulmonary computed tomography findings of adult patients with antibodies to aminoacyl-tRNA synthetases. Eur J Radiol 2016; 85:1421–1426.
[13].Yamasaki Y, Satoh M, Mizushima M, Okazaki T, Nagafuchi H, Ooka S, et al. Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52. Mod. Rheumatol. 2016; 26: 403–409.
[14].Sreevilasan SK, Devarasetti P, Narahari NK, Desai A, Rajasekhar L. Clinical profile and treatment outcomes in antisynthetase syndrome: A tertiary centre experience. Rheumatol. Adv. Pract. 2021; 5 (Suppl. 2): ii10–ii18.
[15].Bauhammer J, Blank N, Max R, Lorenz HM, Wagner U, Krause D, et al. Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response. J Rheumatol 2016; 43:1566–1574.
[16].Johnson SR, Bernstein EJ, Bolster MB, Chung JH, Danoff SK, George MD, et al. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Rheumatol 2024; 76: 1182-1200.
[17].Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. 2013; 40:640–646.
[18].Tsuchiya H, Tsuno H, Inoue M, Takahashi Y, Yamashita H, Kaneko H, et al. Mycophenolate mofetil therapy for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis. Mod. Rheumatol. 2014; 24:694–696.
[19].Intaphan JM, Selvaggio A. Mycophenolate mofetil (MMF) as initial treatment in antisynthetase syndrome - A case report. Am J Resp and Crit Care Med 2016;193:A1539.
[20].Linga K, Robison SW, Lee A , Mira-Avendano I. Retrospective Analysis of Twelve Patients with Anti-Synthetase Syndrome - Mayo Clinic Experience American Journal of Respiratory and Critical Care Medicine 2016;193:A1540.
[21].Ge Y, Zhou H, Shi J, Ye B, Peng Q, Lu X, et al. The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: A systematic review. Clin. Rheumatol. 2015; 34:2097–2103.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Asian Journal of Medicine & Health Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Engineering Technology (JET) is an open-access journal that follows the Creative Commons Attribution-Non-commercial 4.0 International License (CC BY-NC 4.0)
